Day: 2025-04-25

- Hong Kong Investment Promotion Conference – Zhejiang Ningbo Forum cum Ningbo-Hong Kong Economic Co-operation Forum was successfully held in Ningbo, attracting over 600 government and business leaders- Promoted Hong Kong’s role as superconnector and super value-adder to Zhejiang’s business community, focusing on competitive advantages in finance, supply chain, innovation and technology and professional services- Three roundtable sessions facilitated comprehensive business networking between Zhejiang, Ningbo and Hong KongHONG KONG, Apr 25, 2025 - (ACN Newswire via SeaPRwire.com) – The Hong Kong Investment Promotion Conference – Zhejiang Ningbo Forum cum Ningbo-Hong Kong Economic Co-operation Forum, co-organised by the Hong Kong Trade Development Council (HKTDC), the Hong Kong SAR (HKSAR) Government and Ningbo Municipal People’s Government, was held today at the Shangri-La Hotel, Ningbo. The event attracted over 600 government and business leaders who discussed collaboration opportunities among Zhejiang, Ningbo and Hong Kong.The event was held on the 20th anniversary of the Ningbo-Hong Kong Economic Co-operation Forum. Hong Kong’s business advantages were highlighted to Zhejiang government officials as well as business leaders from the finance, supply chain, innovation and technology and professional services sectors. In addition to fostering Zhejiang-Hong Kong and Ningbo-Hong Kong collaboration, Zhejiang enterprises were encouraged to leverage Hong Kong’s platform to explore opportunities.The Forum’s opening ceremony was hosted by Mayor of Ningbo and Deputy Secretary of the CPC Ningbo Municipal Government Tang Feifan this morning, with speeches delivered by the HKSAR Chief Executive John Lee, Executive Vice Director of the Hong Kong and Macao Work Office of the CPC Central Committee and the Hong Kong and Macao Affairs Office of the State Council Zhou Ji, Chief Engineer of the Ministry of Industry and Information Technology Xie Shaofeng, Chief Risk Officer and Director General of the Department of Public Offering Supervision of the China Securities Regulatory Commission Yan Bojin, Vice Governor of Zhejiang Provincial Government Lu Shan, Standing Member of the CPC Zhejiang Provincial Committee and Secretary of the CPC Ningbo Municipal Committee Peng Jiaxue and HKTDC Chairman Dr Peter K N Lam.In his speech, Mr Lee said: "The Hong Kong SAR Government and the HKTDC established a high value-added supply chain service mechanism at the end of last year to help mainland enterprises set up international or regional headquarters in Hong Kong to manage offshore trade and supply chains. Hong Kong has robust international trade networks and rich expertise, diverse talent and world-class professional services. We are well positioned to offer mainland enterprises new supply chain services and lead these businesses in exploring emerging markets, breaking through the US blockade."Mr Zhou stated that the historical ties between Zhejiang and Hong Kong are long-standing, with the two regions sharing close personal relations, cultural connections and commercial linkages. Hong Kong is Zhejiang's largest source of foreign investment, the largest partner in trade in services and second-largest destination for Zhejiang's overseas investments. By the end of 2024, Hong Kong has established over 30,000 enterprises in Zhejiang, while Zhejiang had invested in over 3,000 enterprises in Hong Kong. The mutually beneficial collaboration between Zhejiang and Hong Kong is an exemplary model of regional cooperation between the mainland and Hong Kong.Mr Xie stated that Zhejiang's digital economy is vibrant, with outstanding advantages in industry agglomeration and strong momentum in developing industry and information technology. Ningbo and Hong Kong are both international port cities, sharing a close bond, human connection and commercial ties, with a long-standing history of interaction between the two places. Looking towards the future, the Ministry of Industry and Information Technology will continue to support Ningbo and Hong Kong in strengthening exchange and cooperation, promoting complementary advantages to make new and greater contributions to ensure the prosperity of Hong Kong's economy and the nation's modernisation.Mr Yan said that the China Securities Regulatory Commission fully supports mainland enterprises listing in Hong Kong. In March 2023, the China Securities Regulatory Commission implemented new regulations for overseas listings and established a regulatory coordination mechanism with various ministries. Since implementing the new rules, 141 mainland enterprises have completed the filing process for listing in Hong Kong, including 19 enterprises from Zhejiang. Among these, 13 Zhejiang enterprises and one Ningbo enterprise have completed their listing. These companies are involved in key sectors, such as information technology, biomedicine and consumer goods, contributing to the Hong Kong Stock Exchange ranking fourth globally in IPOs in 2024.He pointed out that the next step for the China Securities Regulatory Commission is to continue improving the institutional mechanism to provide a more transparent, efficient and predictable regulatory environment for overseas listings by enterprises.Mr Lu remarked that Hong Kong would become a "super navigator" for Zhejiang's globalisation efforts, while Zhejiang would become Hong Kong's best partner.He said: "In terms of deepening economic cooperation, Zhejiang enterprises can leverage Hong Kong's international platform to further expand into global markets and enhance their brand visibility. Hong Kong enterprises can also increase their investments in Zhejiang and Ningbo to share the benefits of Mainland China's economic development. In the technology field, we see joint efforts by research institutions and enterprises from both sides, and we believe that more technological innovation and industrialisation will be achieved in both regions."Mr Peng stated that for many years, members of Hong Kong’s Ningbo community have been contributing to the development of Hong Kong and the nation, creating many inspiring stories of patriotism showing love for their hometown and showcasing entrepreneurial innovation.He noted: "In recent years, cooperation between Ningbo and Hong Kong has been greatly advanced and continuously deepened, yielding fruitful results. For the people of Ningbo, Hong Kong is not only the world-renowned 'Pearl of the Orient', but also a vital force driving Ningbo's reform, opening up, and modernisation. It is a place of deep emotional connections and an opportunity-rich city linking us to the wider world. Ningbo will strive to elevate Ningbo-Hong Kong cooperation to new heights."Dr Lam said: “This event showcased Hong Kong’s unique advantages as an international business hub and explored how Zhejiang enterprises, particularly those from Ningbo, can leverage our business platform and partner with our expert professional services to optimise their operations and accelerate their global expansion.”Following the opening ceremony, Deputy Financial Secretary of the HKSAR Government Michael Wong introduced Hong Kong’s advantages, encouraging Zhejiang enterprises to utilise Hong Kong's platform to connect with international markets. He noted that since 2022, over 80 key enterprises have established themselves or expanded their operations in Hong Kong, with 80% coming from Mainland China, including many leading companies across fields, such as AI and robotics, data science, advanced manufacturing, clean energy, life and health technology and fintech.Mr Wong said: "In this era, in which the global economy and international trade face significant challenges, we need to unite and work together more than ever. In Hong Kong, we will leverage our strengths to meet the nation's needs and actively integrate into the country's overall development. We hope to join hands with mainland enterprises to create a better tomorrow."In her keynote speech, Casa Bauhinia Co-Founder Prof Anna Pao Sohmen shared insights on future Zhejiang (Ningbo) - Hong Kong collaboration. She stated that Hong Kong enjoys a long-standing legal system, an open free market and an excellent strategic location, and with the enterprising spirit of Ningbo enterprises, they can surely create golden opportunities.She said: "The pragmatic and open approach of Ningbo, combined with Hong Kong's 'Lion Rock spirit' and can-do approach, will certainly lead to breakthroughs."During the event, Invest Hong Kong signed MOUs with 12 Zhejiang (including Ningbo) enterprise representatives, advancing key Zhejiang-Hong Kong and Ningbo-Hong Kong collaboration projects.Yesterday, HKSAR Chief Executive John Lee and Secretary of the Zhejiang Provincial Committee Wang Hao attended the First Plenary Session of the Hong Kong/Zhejiang Co-operation Conference. The Zhejiang/Hong Kong co-operation mechanism was established during the conference, marking a new chapter for comprehensive exchange and collaboration between the two regions. At the meeting, the two governments signed MoUs on 13 key areas, covering 51 projects. One MoU signed between HKTDC and the Department of Commerce of Zhejiang Province outlined aims for the HKTDC to proactively encourage Hong Kong businesses to invest and expand in Zhejiang, and to also organise trade delegations from various sectors to visit Zhejiang. The two counterparts will continue to explore new areas of trade collaboration to promote high-quality development.During the panel discussion today, distinguished guests – including Chairman of the Hong Kong Science and Technology Parks Corporation Dr Sunny Chai, Chief Executive of Hong Kong Exchanges and Clearing Limited Bonnie Chan; and Chief Executive Officer of the Airport Authority Hong Kong Vivian Cheung – exchanged thoughts on collaboration opportunities in finance, I&T and supply chain. Executive Director and Co-President of Tigermed Hao Wu also shared his company’s success in achieving international growth by leveraging Hong Kong’s platform.The three thematic roundtable sessions held in the afternoon attracted numerous enterprises. Focusing on topics such as listing in Hong Kong, opportunities for innovation and technology companies, and cross-border supply chain management, the sessions brought together institutions and businesses from Hong Kong and Zhejiang for in-depth and targeted discussions on future collaborations.During the event, HKTDC, Invest Hong Kong and the Immigration Department of the HKSAR Government set up consultation booths to provide professional advisory services to attendees.The forum has become an important platform for deepening Zhejiang-Hong Kong collaboration, enabling more mainland enterprises to leverage Hong Kong’s business advantages and partner with its professional services sector to expand globally.Photo download: https://bit.ly/3GonfSlHKSAR Chief Executive John Lee (seventh left), Executive Vice Director of the Hong Kong and Macao Work Office of the CPC Central Committee and the Hong Kong and Macao Affairs Office of the State Council Zhou Ji (sixth left), Chief Engineer of the Ministry of Industry and Information Technology Xie Shaofeng (fifth right), Chief Risk Officer and Director General of the Department of Public Offering Supervision of the China Securities Regulatory Commission Yan Bojin (fourth left), Vice Governor of Zhejiang Provincial Government Lu Shan (fifth left), Standing Member of the CPC Zhejiang Provincial Committee and Secretary of the CPC Ningbo Municipal Committee Peng Jiaxue (sixth right), Mayor of Ningbo and Deputy Secretary of the CPC Ningbo Municipal Government Tang Feifan (second left), HKTDC Chairman Dr Peter K N Lam (third right) and HKTDC Executive Director Margaret Fong (first right) attended Hong Kong Investment Promotion Conference – Zhejiang Ningbo Forum cum Ningbo-Hong Kong Economic Co-operation Forum todayHKSAR Chief Executive John LeeExecutive Vice Director of the Hong Kong and Macao Work Office of the CPC Central Committee and the Hong Kong and Macao Affairs Office of the State Council Zhou JiChief Engineer of the Ministry of Industry and Information Technology Xie ShaofengChief Risk Officer and Director General of the Department of Public Offering Supervision of the China Securities Regulatory Commission Yan BojinVice Governor of Zhejiang Provincial Government Lu ShanStanding Member of the CPC Zhejiang Provincial Committee and Secretary of the CPC Ningbo Municipal Committee Peng JiaxueHKTDC Chairman Dr Peter K N LamDeputy Financial Secretary of the HKSAR Government Michael WongCo-founder of Casa Bauhinia Prof Anna Pao SohmenDuring the panel discussion, distinguished guests, including Chairman of the Hong Kong Science and Technology Parks Corporation Dr Sunny Chai (second left), Chief Executive of Hong Kong Exchanges and Clearing Limited Bonnie Chan (second right); and Chief Executive Officer of the Airport Authority Hong Kong Vivian Cheung (first right), exchanged thoughts on collaboration opportunities in finance, I&T and supply chainDuring the event, Invest Hong Kong signed MOUs with 12 Zhejiang enterprise representatives, advancing key Zhejiang-Hong Kong and Ningbo-Hong Kong collaboration projects. HKTDC, Invest Hong Kong and the Immigration Department of the HKSAR Government set up consultation booths to provide professional advisory services to attendeesMedia enquiriesCity Express (PR agency):Lou JinjingTel: (86) 15005897910Email: loujinjing@hbjt.com.cnLiu YingTel: (86) 15706780806Email: 894353323@qq.comHKTDC’s Shanghai Office:Sun PingTel: (86) 21-63528488Email: p.sun@hktdc.orgHKTDC’s Communications & Public Affairs Department:Jane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年4月25日 - (亞太商訊 via SeaPRwire.com) - 匯聚科技有限公司（「匯聚科技」，股份代號：1729，連同其子公司合稱「集團」）欣然宣布集團截至二零二四年十二月三十一日止年度（「本年度」或「2024財政年度」）的末期財務業績。集團實現了破紀錄的增長，這一成就主要得益於其在高利潤業務的戰略性擴張以及卓越的執行力。於本年度，全球經濟增長放緩，主要受借貸成本高企、財政支持撤回及地緣經濟割裂加劇的影響，整體市場需求遭遇壓力。此外，週期性失衡正逐步消解，主要經濟體的經濟活動逐漸回歸潛在水平。在此複雜的經濟環境中，本集團靈活應對變化，積極推動業務轉型及產品升級，重點把握人工智能崛起所帶動的服務器及數據中心的需求。集團的服務器業務持續成為增長的核心動力，帶動數據中心及特種線分部收益顯著上升。同時，集團亦不斷加大對醫療設備電線業務的投入，進一步擴大客戶群及增強研發實力。集團管理層堅信企業發展與社會責任應相輔相成，積極投身醫療工程與創新發展，透過與業界夥伴攜手合作，致力為香港醫療技術生態注入長遠價值。於本年度，集團錄得的收益為7,388.8百萬港元，較上年度的4,826.3百萬港元增加2562.5百萬港元或53.1%。本年度經營溢利為623.6百萬港元，較上年度的433.4百萬港元增加190.2百萬港元或43.9%，而本年度的經營利潤率則由9.0%輕微下降至8.4%。經營利潤率減少主要歸因於研發成本增加所致，本年度的淨利潤為450.5百萬港元，較上年度的277.6百萬港元加172.9百萬港元或62.3%，而本年度的淨利潤率則由5.8%上升至6.1%*。於本年度，集團每股基本盈利為23.2港仙，而上年度每股基本盈利則為14.2港仙。業務回顧集團各個業務分部的營業額的分布如下:業務分部收益（百萬港元）收益占比截至二零二四年十二月三十一日止年度截至二零二三年十二月三十一日止九個月變化截至二零二四年十二月三十一日止年度截至二零二三年十二月三十一日止九個月電線組件 數據中心1,213.5791.053.4 %16.4%16.4%電訊566.8555.42.1%7.7%11.5%醫療設備816.6258.0216.5%11.1%5.3%工業設備29.224.419.7%0.4%0.5%汽車157.7100.457.1%2.1%2.1%數字電線 網絡電線1,179.9788.749.6%16.0%16.4%特種電線237.077.0207.8%3.2%1.6%服務器3,188.12,231.442.9%43.1%46.2%總計7,388.84,826.353.1%100%100%數據中心分部數據中心分部的收益由上年度的791.0百萬港元大幅增加422.5百萬港元至本年度的1,213.5百萬港元。受惠於人工智能熱潮及服務器升級，出貨水平持續高企，該分部繼續為電線組件業務中收益最高的分部。電訊分部於本年度，電訊分部的收益由上年度的555.4百萬港元增加11.4百萬港元至566.8百萬港元。雖生產資源部分轉向訂單量攀升的數據中心業務，惟電訊分部中利潤較高的訂單得以保留，有助優化整體產品組合。醫療設備分部本集團繼續加大對醫療設備業務的投入，持續擴大其醫療設備客戶群，以及提升研發能力。在去年，受惠於昆山匯聚及江西匯聚兩座新廠房建成，以及拓展醫療設備電線產品的產能及研發能力，該分部的收益大幅增長至816.6百萬港元，比去年258.0百萬港元增加558.6百萬港元。集團管理層預計，隨著健康意識的提高，醫療設備的需求將持續增長。工業設備分部儘管全球經濟復甦步伐較慢，且通脹高企和高利率對經濟活動帶來壓力，集團的工業設備分部的收益仍有所增長。該分部收益由上年度的24.4百萬港元增至本年度的29.2百萬港元，增幅為19.7%。汽車分部儘管受地緣政治及貿易戰影響，汽車配線產品的銷售訂單保持較低水平，但本年度該分部的收益仍增長至157.7百萬港元，比上年度的100.4百萬港元增加57.3百萬港元。集團相信汽車配線產品能為客戶提供更廣泛的產品組合，並通過豐富本集團的業務組合及拓展其獨特的客戶群，踏足新業務領域，以把握電動汽車市場蓬勃發展帶來的機遇。集團在墨西哥成立全資附屬公司司Linkz Cables Mexico S. de R.L. de C.V.（「 Linkz Mexico」），旨在擴大中國及亞洲以外市場的份額。網絡電線分部即使不同國家之間的分歧、戰爭、利率高企、美元走強及通脹偏高等眾多負面因素仍然存在，網絡電線分部的海外訂單仍持續改善，分部收益增至1,179.9百萬港元，較上年度的788.7百萬港元增加391.2百萬港元。銅價上漲顯示市場需求持續增長。此外，Linkz Mexico的成立有助於提升集團在美國及墨西哥市場的市場份額。特種線分部受人工智能應用推動，高速電纜需求顯著增長，帶動特種線分部強勁發展。該分部在本年度收益從上年度的77.0百萬港元，增加160.0百萬港元至237.0百萬港元，增幅達207.8%。高速電纜的增長亦帶動利潤率轉佳，進一步提升本集團整體的盈利能力。服務器分部於本年度，服務器分部收益大幅增長至3,188.1百萬港元，較去年2,231.4百萬港元增加956.7百萬港元。儘管上半年曾受關鍵零件供應短缺影響，但集團積極尋求各種業務解決方案，最終成功恢復生產，令下半年業績回升。服務器的需求持續強勁，亦進一步推動業務增長。展望儘管宏觀經濟環境充滿挑戰，地緣政治緊張更為全球經濟增長帶來更多的不確定性，集團管理層對未來的業務發展依然保持信心，並將秉持靈活應變和持續創新的精神，致力於強化供應鏈韌性、擴大國際佈局及推動多元業務成長，以保障集團的長遠發展。集團於本年度積極拓展海外業務，並已於墨西哥新設全資附屬公司Linkz Mexico。新工廠預期將於年內全面投產，主要生產數字電線及汽車配線產品，有效配合「中國加一」策略，分散地緣風險，保障出口穩定性。面對電動汽車及先進駕駛系統需求迅速增長，汽車線束產品已成為集團下一階段的業務增長驅動力。與此同時，全球5G部署加速、居家辦公與雲端應用常態化等趨勢，進一步推動本集團在電訊線材與伺服器解決方案領域的持續增長。在服務器業務方面，憑藉JDM/ODM業務模式，集團成功拓展數據中心產品線，持續根據品牌客戶的需求深入定制。中國「東數西算」政策將繼續推動相關建設，配合立訊集團的技術平台及市場資源，本集團將進一步擴大數據中心業務規模，抓住人工智能、大數據及雲運算等發展所帶來的龐大市場機遇。集團CEO兼行政總裁柯天然博士對於醫療科技的前景，繼續保持積極的態度：「集團於2024年進一步擴大投資，包括一家具備逾30年營運經驗的日本醫療電子設備公司的股權認購，並投資一間擁有先進穿戴式觸控技術的英國初創企業；藉此拓展智慧健康、復健科技與虛擬醫療應用的新市場。我們相信這兩項投資，將大大強化本集團於醫療設備領域的研發及生產能力，提升產品組合及技術層次。為配合擴展策略，集團已相繼設立兩個新海外聯絡辦事處，即Time US及Time UK，以深化全球業務佈局。」值得一提的是，柯天然博士於2024年促成香港工業總會屬下成立「醫學工程及創新協會」，並出任該協會之聯合主席，與香港工業總會主席及香港新型工業發展聯盟主席莊子雄先生，共同推動醫學工程行業發展。該協會旨在建立醫學工程前沿追蹤機制，深度挖掘技術轉化與商業化潛力；其次構建「政產學研投」全鏈條協同平台，整合政府政策、高校研發、臨床資源與產業資本，設立聯合實驗室及快速轉化通道，加速科研成果產業化；同時強化跨境合作，對接全球創新網絡，引入國際認證機構與技術轉移平台，協助港企突破海外市場準入壁壘，並建立跨境產學研基地，鞏固區域創新樞紐地位；最後實施產業全週期培育計劃，從原型開發、法規認證、臨床試驗到規模生產，為初創企業提供全鏈條支持，同步推動傳統產業轉型與全球市場拓展，助力香港醫療科技產業形成「研發-轉化-產業化」的完整生態，應對全球健康挑戰，提升國際競爭力。集團相信企業在追求業務增長之餘，亦須履行社會企業責任，積極回應健康、創新及產業升級等社會議題的需求。未來集團將立足本土，放眼全球，持續聚焦高潛力領域。透過創新、協同與可持續發展，強化集團業務的核心競爭力，並致力成為領先的網絡解決方案及醫療科技基礎設施供應商，為股東與社會創造更高價值。醫學工程及創新協會成立里程碑關於匯聚科技有限公司匯聚科技有限公司是一家信譽卓著的定制電線互連方案供應商，在行業擁有超過30年經驗。 總部設於香港，並於中華人民共和國(中國)上海、蘇州、江西及惠州，以及日本及墨西哥擁有生產設施。集團目前製造及供應各種銅纜和光纜電線組件、數字電線產品及服務器產品使用在包括電訊、數據中心、工業設備、醫療設備、汽車配線、數字電線及服務器在內的各種市場領域，均受到少商譽優良的中國及國際客戶所採用。本新聞稿由智升公關有限公司代表匯聚科技有限公司發放。如有任何媒體查詢，請聯繫智升公關有限公司：龔小姐電話： (852) 46371627 (852) 6608 9927電郵：ashley.kung@brightcommns.com *備註：匯聚科技的財政年度結束日已於二零二三╱二四年財政期間由三月三十一日變更為於十二月三十一日。因此，本年度的業績涵蓋自二零二四年一月一日至二零二四年十二月三十一日的十二個月期間。務請注意，本新聞稿所呈列之財務資料為與二零二三年四月一日起至二零二三年度十二月三十一日止九個月的財務資料所作之比較。於進行同比比較時，應考慮兩個財政期間時間長短之差異。 Copyright 2025 亞太商訊 via SeaPRwire.com.

SINGAPORE, Apr 25, 2025 - (ACN Newswire via SeaPRwire.com) - The Board of Directors (“Board”) of Mooreast Holdings Ltd. (“Mooreast” or the “Company”), and together with its subsidiaries, the “Group”) wishes to provide an update on several recent developments: Completion of Multi-Buoy Mooring Upgrade Project at Gulf of ThailandFurther to the Company’s announcement dated 12 November 2024, Mooreast wishes to update that the project to upgrade a multi-buoy mooring (“MBM”) system off the eastern shore of the Gulf of Thailand was completed recently. The Group expects to recognise approximately S$8.8 million for this project in the first half of the financial year ending 31 December 2025 (“1H2025”).The successful completion underscores the Group’s capabilities to handle sizeable mooring projects within the oil and gas (“O&G”) industry. Orders related to the O&G sector had been building up in 2H2024, and have continued to gain momentum in the first four months of FY2025. Even with the delivery of the MBM project, current orders at hand are at least equal to those at the end of FY2024. Accordingly, the Group expects revenue in 1H2025 to exceed the S$13.7 million recorded in 1H2024. Additionally, the Group does not expect that the administrative and other operating expenses to increase significantly in FY2025 given that the current staffing is sufficient to support operations and business development in the near term and the absence of fees for professional services rendered to support the Group’s business repositioning efforts in FY2024. Management is actively reviewing and implementing cost control measures to improve overall cost efficiency and profitability moving forward.Update on Floating Wind Energy Projects in Europe and North AsiaOn 1 January 2025, Mr. Eirik Ellingsen (“Mr. Ellingsen”), a Norwegian with deep experience in the offshore and marine sector, was appointed Chief Executive Officer (“CEO”). In the last four months, he has been working closely with Mr. Sim Koon Lam (“Mr Sim”), the founder, Executive Director and Deputy Chairman, on business development strategies amid an increase in commercialisation of floating wind energy projects worldwide.Mr. Ellingsen has been actively engaging players involved in floating wind energy projects in Europe and North Asia, and participated in the WindEurope conference in Copenhagen, Denmark, earlier this month. While the ‘first wave’ of implementation – involving largely demonstration and precommercial projects – had been delayed by the supply chain disruptions caused by the COVID-19 pandemic, the industry has clearly advanced to the ‘second wave’ – commercialisation at scale. With the progress toward commercialisation, the Environmental Resources Management’s “Q3 2024 Global Offshore Wind Market Update" reported over 390 GW of floating wind projects in various planning and development stages. Compared to 50-100 megawatts (“MW”) typical at pre-commercialisation, the latter involves projects of at least 500 MW each. Many of these projects are reaching the final investment decision (“FID”) phase in 2026 and 2027. These include multigigawatt (“GW”) scale projects which can contribute substantially to the growth of offshore wind capacity globally. Typically, mooring and rigging solutions, including anchors, chains, and ropes, account for between 5% to 10% of the total value of each floating wind energy project. Approximately 5.5 GW of floating wind capacity is expected to reach FID in the next 24-36 months. Of this, about two-thirds involve projects in Europe, including those in the North Sea, while a third will come from North Asia. These projects may be deemed as the addressable market of Mooreast. As the Group is currently not targeting U.S. floating wind energy projects, it is not subject to U.S. Government tariffs for its products. Already, Mooreast is working closely with these projects and has indicated its component costings. As these progress to full implementation, developers and partners are looking for a reliable manufacturer capable of handling the large volumes of anchors and mooring components required for these large-scale projects. The Group believes it is uniquely positioned, given its status as Asia’s only ultra-high power anchor designer and manufacturer and its global footprint. Mooreast recently opened new offices in Taiwan and Malaysia in June and July 2024, respectively, expanding its presence in the Asian region.The Group continues to assess the ability of its present facility at 51 Shipyard Road in Singapore to handle production of anchors and components as these projects advance to formal tender, noting that developers have indicated suppliers would need to demonstrate beforehand sufficient capacity to handle the indicative volume. Should such orders escalate beyond the current capacity of the existing yard, Mooreast would need to explore access to additional capacity. Meanwhile, the Company continues to develop its supply chain to better serve its customers globally. The Company will provide updates to shareholders as and when there are material developments regarding floating renewable energy projects. BY ORDER OF THE BOARD MOOREAST HOLDINGS LTD.Mr Eirik Ellingsen Chief Executive Officer23 April 2025This announcement has been reviewed by the Company’s sponsor, UOB Kay Hian Private Limited (the “Sponsor”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881. Copyright 2025 ACN Newswire via SeaPRwire.com.

- Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in the number and suppressive function of Tregs compared to baseline values. - Clinically, patients with Frontotemporal Dementia (FTD) demonstrated minimal to no cognitive decline throughout the study period. Treatment was well tolerated, no serious adverse events were reported, and all 5 patients completed the study.Houston, TX, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) - Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute (Houston, TX) with funding from The Peggy and Gary Edwards Endowment Fund. Study patients received subcutaneously administered CTLA4-Ig, followed by a 5-day course of low-dose IL-2 every four weeks, for a total of 22 weeks of dosing and follow-up. The study aims to enroll up to 10 patients, and these interim results include data from the first 5 patients with mild to moderate FTD who have completed the full course of treatment.Dr. Arun Swaminathan, Coya’s Chief Executive Officer followed: “The results thus far are consistent with previously published encouraging data from an open-label investigator-initiated study of patients with ALS treated with low-dose IL-2/CTLA4-Ig. This interim data in FTD provides us further confidence of our approach to target and enhance Treg biology to address devastating neurodegenerative diseases including ALS and FTD”.Previous biomarker data presented by the Company demonstrated that FTD patients exhibit a compromised immunosuppressive function of regulatory T cells (Tregs), along with increased peripheral levels of inflammatory cytokines and chemokines, dysregulation of monocytes, and systemic activation of the inflammatory cascade, supporting the critical role of the immune system in the pathophysiology of FTD.One previous study showed that a cohort of 68 patients with FTD worsened by an average of 3.57 points over a 12-month period per the Clinical Dementia Rating - Frontotemporal Lobar Degeneration (CDR‐FTLD) scale (Knopman et al. Brain 2008; 131(11): 2957-2968). In addition, patients with FTD typically have shorter survival times and more rapid rates of cognitive and functional decline compared to patients with Alzheimer’s disease (Rascovsky et al. Neurology 2005; 65(3): 397-403).Dr. Fred Grossman, Coya’s Chief Medical Officer stated: “We are excited with the results observed in this initial group of patients with this proof-of-concept study. We believe that the increase in Treg numbers and suppressive function, with subsequent anti-inflammatory biological activity still to be evaluated, underscores the potential for this low-dose IL-2/CTLA4-Ig combination to be further studied as a therapy for FTD, for which there are no currently approved treatments.”Summary of Interim Study Results Overall, treatment with low-dose IL-2 and CTLA4-Ig was well tolerated. All 5 patients enrolled in the first cohort completed the study and received the investigational treatment as planned. The most common adverse events were mild injection site reactions. No serious adverse events were reported.Treg numbers and suppressive function increased after the first treatment cycle (p < 0.01 and p < 0.05, respectively, and remained at higher significant levels throughout the treatment period.Clinical functional assessments were performed in all patients at pre-specified timepoints over the course of the study using validated tools, including the Clinical Dementia Rating - Frontotemporal Lobar Degeneration (CDR‐FTLD) scale, the Montreal Cognitive Assessment (MoCA) scale, and the Progressive Aphasia Severity Scale (PASS). Results of the functional tests show that, on average, these five FTD patients treated with low-dose IL-2 and CTLA4-Ig combination exhibited minimal to no cognitive decline over the course of the study, compared to pre-treatment values.The Company intends to publish and/or present more comprehensive data in a future peer-reviewed meeting and/or publication.About Frontotemporal DementiaFrontotemporal dementia (FTD) refers to a group of neurodegenerative disorders characterized by altered behavior and language, with a progressive decline in executive function.1 FTD affects an estimated 30,000 Americans.2 FTD is categorized clinically into various subtypes; the main three include behavioral-variant frontotemporal dementia and two language variants, semantic dementia (also known as semantic variant primary progressive aphasia) and progressive non-fluent aphasia (also known as non-fluent variant primary progressive aphasia). It's a presenile dementia, meaning it can occur in younger individuals, often between the ages of 45 and 64. The average age of onset is 58, with an average survival time of 7.5 years.1,2References1. Knopman et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 2008; 131(11): 2957-29682. Rascovsky et al. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 2005; 65(3): 397-403About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.COYA 302 is a combination treatment comprised of low-dose IL-2 and CTLA4-Ig is an investigational therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of Tregs and suppress the inflammation produced by activated monocytes and macrophages. Coya is developing COYA 302 for the treatment of fatal neurogenerative diseases characterized by chronic inflammation and Treg dysfunction.For more information about Coya, please visit www.coyatherapeutics.com Forward-Looking StatementsThis press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Investor Contact:David Snyder, CFOdavid@coyatherapeutics.com CORE IRBret Shapirobrets@coreir.com 561-479-8566Media ContactsFor Coya Therapeutics:Kati Waldenburgmedia@coyatherapeutics.com212-655-0924 Copyright 2025 ACN Newswire via SeaPRwire.com.